Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CTCE 9908 acetate is an antagonist of CXCR4 and inhibits migration in CXCR4-expressing ovarian cancer cells.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 257.00 | |
2 mg | In stock | $ 411.00 | |
5 mg | In stock | $ 626.00 | |
10 mg | In stock | $ 939.00 | |
25 mg | In stock | $ 1,380.00 | |
50 mg | In stock | $ 1,890.00 | |
100 mg | In stock | $ 2,550.00 |
Description | CTCE 9908 acetate is an antagonist of CXCR4 and inhibits migration in CXCR4-expressing ovarian cancer cells. |
In vitro | CTCE 9908 acetate inhibited ovarian cancer cell migration to CXCL12, but on longer incubation, caused cell death in CXCR4-positive cells. CTCE 9908 acetate did not cause apoptosis or cellular senescence, but induced multinucleation, G(2)-M arrest, and abnormal mitosis in ovarian cancer cells. CTCE 9908 acetate deregulated DNA damage checkpoint proteins and spindle assembly checkpoint proteins at G(2)-M phases of the cell cycle. Combination treatment of CTCE 9908 acetate and the drug paclitaxel led to an additive cytotoxicity that also involved mitotic catastrophe[1]. |
In vivo | In dosing experiment of CTCE 9908 acetate in the PyMT mouse model, increasing doses of CTCE 9908 acetate alone slowed the rate of tumor growth, with a 45% inhibition of primary tumor growth at 3.5 weeks of treatment with 50 mg/kg of CTCE 9908 acetate (p = 0.005). Expression levels of VEGF were also found to be reduced by 42% with CTCE 9908 acetate (p = 0.01). In combination with docetaxel, CTCE 9908 acetate administration decreased tumor volume by 38% (p = 0.02), an effect that was greater than that observed with docetaxel alone. In combination with DC101, CTCE 9908 acetate also demonstrated an enhanced effect compared to DC101 alone, with a 37% decrease in primary tumor volume (p = 0.01) and a 75% reduction in distant metastasis (p = 0.009). In combination with docetaxel or an anti-angiogenic agent, the anti-tumor and anti-metastatic effects of CTCE 9908 acetate were markedly enhanced[2]. |
Molecular Weight | 1987.31 |
Formula | C88H151N27O25 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
CTCE 9908 acetate Autophagy GPCR/G Protein Immunology/Inflammation CXCR CTCE 9908 Acetate CTCE-9908 Acetate CTCE9908 Acetate inhibitor inhibit